300 related articles for article (PubMed ID: 36283420)
21. PARP Inhibition in Advanced Prostate Cancer.
Fenton SE; Chalmers ZR; Hussain M
Cancer J; 2021 Nov-Dec 01; 27(6):457-464. PubMed ID: 34904808
[TBL] [Abstract][Full Text] [Related]
22. Identification of DNA Damage Repair-Associated Prognostic Biomarkers for Prostate Cancer Using Transcriptomic Data Analysis.
Teng PC; Huang SP; Liu CH; Lin TY; Cho YC; Lai YL; Wang SC; Yeh HC; Chuu CP; Chen DN; Cheng WC; Li CY
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769200
[TBL] [Abstract][Full Text] [Related]
23. Germline DNA Damage Response Gene Mutations in Localized Prostate Cancer.
Januskevicius T; Vaicekauskaite I; Sabaliauskaite R; Matulevicius A; Vezelis A; Ulys A; Jarmalaite S; Jankevicius F
Medicina (Kaunas); 2023 Dec; 60(1):. PubMed ID: 38256334
[No Abstract] [Full Text] [Related]
24. Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics.
Gong J; Posadas E; Bhowmick N; Kim H; Daskivich T; Gupta A; Sandler H; Kamrava M; Zumsteg Z; Freedland S; Figlin R
Oncology (Williston Park); 2021 Mar; 35(3):119-125. PubMed ID: 33818052
[TBL] [Abstract][Full Text] [Related]
25. PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells.
Yin L; Liu Y; Peng Y; Peng Y; Yu X; Gao Y; Yuan B; Zhu Q; Cao T; He L; Gong Z; Sun L; Fan X; Li X
J Exp Clin Cancer Res; 2018 Jul; 37(1):153. PubMed ID: 30012171
[TBL] [Abstract][Full Text] [Related]
26. Defective DNA repair mechanisms in prostate cancer: impact of olaparib.
De Felice F; Tombolini V; Marampon F; Musella A; Marchetti C
Drug Des Devel Ther; 2017; 11():547-552. PubMed ID: 28280302
[TBL] [Abstract][Full Text] [Related]
27. Targeting DNA damage repair pathways in pancreas cancer.
Crowley F; Park W; O'Reilly EM
Cancer Metastasis Rev; 2021 Sep; 40(3):891-908. PubMed ID: 34403012
[TBL] [Abstract][Full Text] [Related]
28. Genetic Aberrations of DNA Repair Pathways in Prostate Cancer: Translation to the Clinic.
Ghose A; Moschetta M; Pappas-Gogos G; Sheriff M; Boussios S
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575947
[TBL] [Abstract][Full Text] [Related]
29. A Prognostic Model for Prostate Cancer Patients Based on Two DNA Damage Response Mutation-Related Immune Genes.
Wang J; Jiang L; Shang Z; Ye Z; Yuan D; Cui X
Cancer Biother Radiopharm; 2024 May; 39(4):306-317. PubMed ID: 37610864
[No Abstract] [Full Text] [Related]
30. Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer.
van der Doelen MJ; Isaacsson Velho P; Slootbeek PHJ; Pamidimarri Naga S; Bormann M; van Helvert S; Kroeze LI; van Oort IM; Gerritsen WR; Antonarakis ES; Mehra N
Eur J Cancer; 2020 Sep; 136():16-24. PubMed ID: 32634759
[TBL] [Abstract][Full Text] [Related]
31. PARP inhibitors in advanced prostate cancer: when to use them?
Díaz-Mejía N; García-Illescas D; Morales-Barrera R; Suarez C; Planas J; Maldonado X; Carles J; Mateo J
Endocr Relat Cancer; 2021 Jul; 28(8):T79-T93. PubMed ID: 34256353
[TBL] [Abstract][Full Text] [Related]
32. Roles of the PARP Inhibitor in
Inoue T; Sekito S; Kageyama T; Sugino Y; Sasaki T
Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174127
[TBL] [Abstract][Full Text] [Related]
33. Triggering pyroptosis enhances the antitumor efficacy of PARP inhibitors in prostate cancer.
Tian A; Wu T; Zhang Y; Chen J; Sha J; Xia W
Cell Oncol (Dordr); 2023 Dec; 46(6):1855-1870. PubMed ID: 37610690
[TBL] [Abstract][Full Text] [Related]
34. BRCA2 and Other DDR Genes in Prostate Cancer.
Nombela P; Lozano R; Aytes A; Mateo J; Olmos D; Castro E
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30871108
[TBL] [Abstract][Full Text] [Related]
35. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
[TBL] [Abstract][Full Text] [Related]
36. DNA Repair in Prostate Cancer: Biology and Clinical Implications.
Mateo J; Boysen G; Barbieri CE; Bryant HE; Castro E; Nelson PS; Olmos D; Pritchard CC; Rubin MA; de Bono JS
Eur Urol; 2017 Mar; 71(3):417-425. PubMed ID: 27590317
[TBL] [Abstract][Full Text] [Related]
37. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
Martin GA; Chen AH; Parikh K
Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
[TBL] [Abstract][Full Text] [Related]
38. Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy.
Gourley C; Balmaña J; Ledermann JA; Serra V; Dent R; Loibl S; Pujade-Lauraine E; Boulton SJ
J Clin Oncol; 2019 Sep; 37(25):2257-2269. PubMed ID: 31050911
[TBL] [Abstract][Full Text] [Related]
39. Olaparib for the treatment of metastatic prostate cancer.
Dror CM; Wyatt AW; Chi KN
Future Oncol; 2021 Jul; 17(19):2413-2429. PubMed ID: 33769071
[TBL] [Abstract][Full Text] [Related]
40. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS
Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
